CureVac says well on track to request COVID-19 vaccine approval as planned
Germany's CureVac is on ทางเข้าเล่นslotxo track to file for European approval of its COVID-19
vaccine as early as this month because high infection rates among trial participants are bringing
a read-out on efficacy within closer reach.
"The cases are coming in fast," Chief Executive Franz-Werner Haas told Reuters.
Since starting out in 2000, the biotech firm has focused on so-called messenger RNA (mRNA),
a drug and vaccine technology that has also become the recent focus of the European union's
procurement negotiations.
The mRNA approach has been validated by the wide use of coronavirus vaccines developed by
pioneers BioNTech and its partner Pfizer, as well as by Moderna, in Europe and North America.
But more volumes will be needed to boost lagging immunisation coverage in Europe and
potentially for repeated booster shots.
The group's late stage trial involves more than 37,000 volunteers in Europe and Latin America,
half of whom are receiving a placebo.
An interim analysis is due when 56 and then 111 volunteers across both groups have fallen
ill with COVID-19.
CureVac has not publicly determined at which checkpoint it would publish first results but has
said it expects to file for European authorisation in late May or early June.
Current infection rates in participating country Peru, in particular, have put CureVac well
on track to meet its timetable, Haas said.
As CureVac's only major supply deal, the European Union in November last year secured up
to 405 million doses of the shot, of which 180 million are optional.
|
|